Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...

UK pharmaceutical giant GSK has confirmed that it has signed an agreement to acquire the privately-held biotechnology company ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

This morning, the UK pharma group confirmed it had signed an agreement to buy privately-held IDRx for $1 billion upfront, ...

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

Italian authorities released the director of a notorious detention camp who had been arrested in Turin on an ICC war crimes warrant. Italian police were acting on an arrest warrant from the ...

Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news – Get the most important news from ...

The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...

US FDA grants breakthrough therapy designation to GSK’s B7-H3-targeted ADC, GSK’227 to treat relapsed or refractory osteosarcoma: London, UK Wednesday, January 8, 2025, 10:00 ...

The breakthrough therapy designation for GSK5764227 is supported by data from the phase 2 ARTEMIS-002 trial. The US Food and Drug Administration (FDA) has granted breakthrough therapy designation ...

Attacks between guerrilla groups have also seen thousands displaced from the country's Catatumbo region. The increased reward was announced on the day Maduro was sworn in for a third six-year term ...